Pharmacokinetics and pharmacodynamics of ASKP1240, a fully human anti-CD40 antibody, in normal and renal transplanted cynomolgus monkeys

Transplantation

Volumn 97, Issue 4, 2014, Pages 397-404

  Ma, Anlun ^a   Dun, Hao ^a   Song, Lijun ^a   Hu, Yanxin ^a   Zeng, Lin ^b   Bai, Jieying ^b   Zhang, Guangzhou ^b   Kinugasa, Fumitaka ^c   Miyao, Yasuhiro ^d   Sakuma, Shozo ^d   Okimura, Kazumichi ^e   Kasai, Noriyuki ^e   Daloze, Pierre ^a   Chen, Huifang ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^d ASTELLAS PHARMA INC   (Japan)

^e KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ASKP 1240; CD40 ANTIGEN; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG PROTEIN BINDING; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MACACA FASCICULARIS; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD40; BIOTINYLATION; CELL SEPARATION; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MACACA FASCICULARIS; MALE; TIME FACTORS;

EID: 84896727570     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000440951.29757.bd     Document Type: Article

References (30)

1. Kempen JH, Gangaputra S, Daniel E, et al. Long-Term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: A critical assessment of the evidence. Am J Ophthalmol 2008; 146: 802.
2. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 10: 931.
3. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
4. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1581.
5. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapyrefractory chronic graft-versus-host disease. Blood 2004; 104: 2603.
6. Blair PA, Chavez-Rueda KA, Evans JG, et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol 2009; 182: 3492.
7. Yang Y, Wilson JM. CD40 ligand-dependent T cell activation: Requirement of B7-CD28 signaling through CD40. Science 1996; 273: 1862.
8. Grewal IS, Foellmer HG, Grewal KD, et al. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 1996; 273: 1864.
9. Larsen CP, Elwood ET, Alexander DZ, et al. Long-Term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
10. Yamashita K, Masunaga T, Yanagida N, et al. Long-Term acceptance of rat cardiac allografts on the basis of adenovirus mediated CD40Ig plus CTLA4Ig gene therapies. Transplantation 2003; 76: 1089.
11. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686.
12. Montgomery SP, Xu H, Tadaki DK, et al. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation 2002; 74: 1365.
13. Xu H, Tadaki DK, Elster EA, et al. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Transplantation 2002; 74: 940.
14. Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114.
15. Koyama I, Kawai T, Andrews D, et al. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 2004; 77: 460.
16. Kanmaz T, Fechner JJ Jr, Torrealba J, et al.Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. Transplantation 2004; 77: 914.
17. Watanabe M, Yamashita K, Suzuki T, et al. ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates. Am J Transplant 2013; 13: 1976.
18. Oura T, Yamashita K, Suzuki T, et al. Long-Term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates. Am J Transplant 2012; 12: 1740.
19. Weaver TA, Charafeddine AH, Kirk AD. Costimulation blockade: Towards clinical application. Front Biosci 2008; 13: 2120.
20. Goldwater R, Keirns J, Blahunka P, et al. A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. Am J Transplant 2013; 13: 1040.
21. Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 2007; 84: 1020.
22. Song L, Ma A, Dun H, et al. A novel fully human anti-CD40 monoclonal antibody, ASKP1240, mono-And combination-Therapy in prolongation of renal allograft survival in Cynomolgus monkeys [abstract]. Am J Transplant 2011; 11(Suppl 2): 438.
23. Ma A, Dun H, Song L, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) studies of ASKP1240, a novel fully human anti-CD40 monoclonal antibody in normal and transplanted Cynomolgus monkeys [abstract]. Am J Transplant 2011; 11(Suppl 2): 348.
24. Crow AR, Leytin V, Starkey AF, et al. CD154 (CD40 ligand)-deficient mice exhibit prolonged bleeding time and decreased shear-induced platelet aggregates. J Thromb Haemost 2003; 1: 850.
25. Freedman JE. CD40-CD40L and Platelet Function. Circulation Research 2003; 92: 944.
26. Kanmaz T, Fechner JJ Jr, Torrealba J, et al.Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. Transplantation 2004; 77: 914.
27. Qi S, Xu D, Peng J, et al. Effect of tacrolimus (FK506) and sirolimus (rapamycine) mono-And combination therapy in prolongation of renal allograft survival in the monkey. Transplantation 2000; 69: 1275.
28. Chen H, Peng J, Luo H, et al. Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus. Transplantation 2000; 69: 1555.
29. Qi S, Zhu S, Xu S, et al. Significant prolongation of renal allograft survival by delayed combination therapy of FK778 with tacrolimus in nonhuman primates. Transplantation 2003; 75: 1124.
30. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.